Table 1.

Patient Characteristics.

Characteristic	Definitive RT only (N=101)	Sequential CRT (N=235)
Gender, No. (%)
Male	49 (49)	129 (55)
Female	52 (51)	106 (45)
Age, median (range), y	78 (51–93)	71 (32–91)
Patients aged >70, No. (%)	80 (79)	119 (51)
KPS, median (range)	80 (40–90)	80 (40–100)
No. patients with KPS <80	47 (47)	59 (25)
Smoking history, No. (%)
Former	71 (70)	149 (63)
Current	24 (24)	70 (30)
Never	6 (6)	16 (7)
Stage, No. (%)
IIA	20 (20)	7 (3)
IIB	14 (14)	8 (3)
IIIA	46 (46)	135 (57)
IIIB	21 (21)	85 (36)
Primary tumor radiographic size, median (range), cm	3.9 (0.6–12.2)	4.1 (0.9–12.4)
GTV, median (range), cc	91.9 (1.9–630.4)	67.4 (2.5–762.2)
Histology, No. (%)
Squamous cell	47 (47)	77 (33)
Adenocarcinoma	42 (42)	123 (52)
Other/NOS	12 (12)	35 (15)
Radiation treatment, No. (%)
Definitive RT only	101 (100)	-
Sequential CRT	-	235 (100)
Chemotherapy regimen in sequential CRT patients, No. (%)
Platinum doublet	-	220 (94)
Platinum-gemcitabine	-	42 (19)
Platinum-pemetrexed	-	60 (27)
Carboplatin-paclitaxel	-	49 (22)
Other platinum doublet	-	69 (31)
Other chemotherapy	-	14 (6)
Radiation technique, No. (%)
3D-CRT	30 (30)	47 (20)
IMRT	71 (70)	188 (80)
Radiation dose, median (range), Gy	66.0 (50.0–80.0)	64.8 (50.0–80.0)
Radiation dose No. (%), Gy
<60.0	13 (13)	42 (18)
60.0 to 66.0	40 (40)	122 (52)
>66.0	48 (48)	71 (30)
Overall survival, median (range), mo	20.2 (3.0–118.8)
Follow-up time for survivors, median (range), mo	38.6 (3.4–118.8)

KPS: Karnofsky performance status, GTV: primary and nodal gross tumor volume, NOS: not otherwise specified, RT: radiotherapy, CRT: chemoradiation, 3D-CRT: three-dimensional conformal radiation therapy, IMRT: intensity-modulated radiation therapy, Gy: Gray